Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Brain cross‐protection against SARS‐CoV‐2 variants by a lentiviral vaccine in new transgenic mice

15 Oct 2021

Abstract excerpt

COVID-19 vaccines already in use or in clinical development may have reduced efficacy against emerging SARS-CoV-2 variants. In addition, although the neurotropism of SARS-CoV-2 is well established, the vaccine strategies currently developed have not taken into account protection of the central nervous system. Here, we generated a transgenic mouse strain expressing the human angiotensin-converting enzyme 2, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to Long-Term Effects of COVID-19
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34647691
DOI: 10.15252/emmm.202114459

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Brain cross‐protection against SARS‐CoV‐2 variants by a lentiviral vaccine in new transgenic micePMID 34647691Read ↗

Brain and Lung Cross-Protection against Ancestral or Emerging SARS-CoV-2 by Intranasal Lentiviral Vaccination in a New hACE2 Transgenic Murine ModelSemantic proximity Read ↗

Full Brain and Lung Prophylaxis against SARS-CoV-2 by Intranasal Lentiviral Vaccination in a New hACE2 Transgenic Mouse Model or Golden HamstersSemantic proximity Read ↗

Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2Semantic proximity Read ↗

A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infectionSemantic proximity Read ↗

Sex-biased response to and brain cell infection by SARS-CoV-2 in a highly susceptible human ACE2 transgenic modelSemantic proximity Read ↗

CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2Semantic proximity Read ↗

Mice Humanized for Major Histocompatibility Complex and Angiotensin-Converting Enzyme 2 with High Permissiveness to SARS-CoV-2 Omicron ReplicationSemantic proximity Read ↗

Characterization of low copy number human angiotensin-converting enzyme 2 (hACE2)-transgenic mice as an improved model of SARS-CoV-2 infectionSemantic proximity Read ↗

Neuroinvasion and neurotropism by SARS-CoV-2 variants in the K18-hACE2 mouseSemantic proximity Read ↗

Differential Patterns of Cross-Protection against Antigenically Distinct Variants in Small Animal Models of SARS-CoV-2 InfectionSemantic proximity Read ↗

Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic MiceSemantic proximity Read ↗

Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.